Tagarakis Georgios I
Department of Cardiovascular and Thoracic Surgery, University of Thessaly, Larissa, Greece.
Recent Pat Cardiovasc Drug Discov. 2010 Nov;5(3):208-11. doi: 10.2174/157489010793351908.
The need for safe and effective antiplatelet agents motivates scientists towards a non-ceasing research which has through the past few years provided patients suffering from coronary artery disease, submitted or not to percutaneous intervention or heart surgery with safe and life-saving pharmaca; after ticlopidine and clopidogrel and just recently, ticagrelor and prasugrel have been developed with the aim to provide adequate protection against thrombotic cardiovascular episodes and avoid significant bleeding events. Herein, we are presenting through an updated literature research and recent patents data the novel agents ticagrelor and prasugrel, which promise improved effectiveness combined with an increased level of safety.
对安全有效的抗血小板药物的需求促使科学家们不断进行研究，在过去几年中，这些研究为患有冠状动脉疾病的患者提供了安全且能挽救生命的药物，无论他们是否接受经皮介入治疗或心脏手术；继噻氯匹定和氯吡格雷之后，最近又研发出了替格瑞洛和普拉格雷，目的是提供足够的保护以预防血栓性心血管事件，并避免严重出血事件。在此，我们通过最新的文献研究和近期的专利数据介绍新型药物替格瑞洛和普拉格雷，它们有望提高疗效并提升安全性。
